Adults with ADHD treated with CONCERTA OROS methylphenidate HCl extended-release tablets showed significant improvements in ADHD symptom management compared to adults taking placebo, according to study results presented today at a major psychiatric medical meeting.
"Pharmacological treatment of children and adolescents with ADHD is clearly established but relatively less is known about the treatment of adults with ADHD," notes the study's medical director, Sally Berry, M.D., PhD., of Johnson & Johnson Pharmaceutical Research and Development, LLC. "We're encouraged that the CONCERTA® findings presented today -- in which CONCERTA® significantly improved ADHD symptom management in adults -- can benefit the growing body of knowledge in this important therapeutic area."
Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder that affects normal behavior and impairs the ability to concentrate.
The data presented today are part of a Supplemental New Drug Application (sNDA) submitted in August 2007 to the Food and Drug Administration for use of CONCERTA® to treat adults with ADHD. CONCERTA® is already approved for the treatment of ADHD in children and adolescents ages six to 17.
VEN/S
Advertisement
|
Recommended Readings
Latest Drug News
